EA201790101A1 - Аналоги придопидина, их получение и применение - Google Patents

Аналоги придопидина, их получение и применение

Info

Publication number
EA201790101A1
EA201790101A1 EA201790101A EA201790101A EA201790101A1 EA 201790101 A1 EA201790101 A1 EA 201790101A1 EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A1 EA201790101 A1 EA 201790101A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
methylsulfonyl
dopopidine
provides
present
Prior art date
Application number
EA201790101A
Other languages
English (en)
Inventor
Малле Шмидт
Малле Пэри
Марит Лаос
Антс Масалу
Калле Кальйусте
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201790101A1 publication Critical patent/EA201790101A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities

Abstract

В данном изобретении представлено выделенное соединение, имеющее структуру:или его соль. В данном изобретении также представлен способ получения 4-(3-(метилсульфонил)фенил)-1-пропилпиперидин-4-ола, 1-(3,3-бис-(3-(метилсульфонил)фенил)пропил)-4-(3-(метилсульфонил)фенил)пиперидона, 1,4-бис-((3-(1-пропилпиперидин-4-ил)фенил)сульфонил)бутана, (3R,4S)-4-(3-(метилсульфонил)фенил)-1-пропилпиперидин-3-ола, 1-оксида 4-(3-(метилсульфонил)фенил)-1-пропилпиперидина, 1-(2-метилпентил)-4-(3-(метилсульфонил)фенил)пиперидина, 4-(3-(метилсульфинил)фенил)-1-пропил-1,2,3,6-тетрагидропиридина и 4-(3-(метилсульфонил)фенил)-1-пропил-1,2,3,6-тетрагидропиридина. В данном изобретении также представлена примесь или ее соль для применения, в качестве ссылочного стандарта, для определения следов примеси в фармацевтической композиции, содержащей придопидин или его фармацевтически приемлемую соль. В данном изобретении также представлен способ получения лекарственного продукта придопидина, включающий получение лекарственного вещества придопидина и смешивания лекарственного вещества придопидина с подходящими наполнителями с получением лекарственного продукта придопидина. В данном изобретении также представлен способ получения лекарственного продукта придопидина. В данном изобретении также представлен способ продажи лекарственного продукта придопидина.
EA201790101A 2014-06-30 2015-06-29 Аналоги придопидина, их получение и применение EA201790101A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019337P 2014-06-30 2014-06-30
US201462076436P 2014-11-06 2014-11-06
PCT/US2015/038349 WO2016003919A1 (en) 2014-06-30 2015-06-29 Analogs of pridopidine, their preparation and use

Publications (1)

Publication Number Publication Date
EA201790101A1 true EA201790101A1 (ru) 2017-06-30

Family

ID=54929343

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790101A EA201790101A1 (ru) 2014-06-30 2015-06-29 Аналоги придопидина, их получение и применение

Country Status (18)

Country Link
US (3) US10130621B2 (ru)
EP (2) EP3160470B1 (ru)
JP (2) JP6800842B2 (ru)
CN (2) CN106456618A (ru)
AU (1) AU2015284385B2 (ru)
BR (1) BR112016030968B1 (ru)
CA (1) CA2951494C (ru)
DK (1) DK3160470T3 (ru)
EA (1) EA201790101A1 (ru)
ES (1) ES2927888T3 (ru)
HK (1) HK1231406A1 (ru)
HU (1) HUE060242T2 (ru)
IL (2) IL249601B (ru)
MX (1) MX2016017332A (ru)
PL (1) PL3160470T3 (ru)
TW (1) TW201613859A (ru)
UY (1) UY36192A (ru)
WO (1) WO2016003919A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US11090297B2 (en) * 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX2015017307A (es) 2013-06-21 2016-08-03 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
BR112019015000A2 (pt) 2017-01-20 2020-04-07 Agency Science Tech & Res uso de pridopidina para o tratamento da síndrome do x frágil
JP7082186B2 (ja) 2017-08-14 2022-06-07 プリレニア ニューロセラピューティクス リミテッド プリドピジンによる筋萎縮性側索硬化症の治療方法
CN111278431A (zh) 2017-08-30 2020-06-12 普瑞尼亚神经治疗有限公司 普利多匹定的高浓度剂型
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
MX2021011269A (es) * 2019-03-15 2021-10-01 Prilenia Neurotherapeutics Ltd Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
BR112021024744A2 (pt) * 2019-06-12 2022-03-22 Prilenia Neurotherapeutics Ltd Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
AU2021266476A1 (en) * 2020-05-04 2022-11-24 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective S1R agonist
CA3192542A1 (en) * 2020-10-20 2022-04-28 Michael Hayden Use of pridopidine and analogs for the treatment of anxiety and depression
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CN117202906A (zh) * 2021-04-14 2023-12-08 普瑞尼亚神经治疗有限公司 前驱亨廷顿病的治疗
CN114716391B (zh) * 2022-04-24 2023-12-12 杭州仟源保灵药业有限公司 一种醋甲唑胺杂质及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
MXPA06013945A (es) * 2004-06-08 2007-10-08 Neurosearch Sweden Ab Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2578750A1 (en) * 2004-09-04 2006-03-16 Teva Pharmaceutical Industries, Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
CN101056854B (zh) * 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
AU2005293755A1 (en) * 2004-10-13 2006-04-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
WO2006073519A1 (en) * 2005-01-03 2006-07-13 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
AU2008239841B2 (en) * 2007-04-12 2013-07-18 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
JP6189299B2 (ja) 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
CN104470585A (zh) 2012-04-04 2015-03-25 爱华克斯国际有限公司 用于联合疗法的药物组合物
AU2013323133A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015017307A (es) 2013-06-21 2016-08-03 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
EP3096759B1 (en) 2014-01-22 2022-04-06 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina

Also Published As

Publication number Publication date
CN113511997A (zh) 2021-10-19
DK3160470T3 (da) 2022-10-24
IL272306A (en) 2020-03-31
MX2016017332A (es) 2017-05-12
ES2927888T3 (es) 2022-11-11
JP2020143072A (ja) 2020-09-10
CN106456618A (zh) 2017-02-22
US20190030016A1 (en) 2019-01-31
IL249601B (en) 2020-01-30
EP3160470A4 (en) 2018-01-10
US10406145B2 (en) 2019-09-10
AU2015284385B2 (en) 2021-01-21
UY36192A (es) 2016-01-29
CA2951494C (en) 2023-10-03
HUE060242T2 (hu) 2023-02-28
US10130621B2 (en) 2018-11-20
WO2016003919A1 (en) 2016-01-07
JP2017519839A (ja) 2017-07-20
EP4049998A1 (en) 2022-08-31
TW201613859A (en) 2016-04-16
US20200030308A1 (en) 2020-01-30
CA2951494A1 (en) 2016-01-07
US20150374677A1 (en) 2015-12-31
JP6800842B2 (ja) 2020-12-16
EP3160470A1 (en) 2017-05-03
BR112016030968A2 (pt) 2018-07-17
WO2016003919A8 (en) 2017-01-26
IL249601A0 (en) 2017-02-28
HK1231406A1 (zh) 2017-12-22
US11141412B2 (en) 2021-10-12
AU2015284385A1 (en) 2017-02-02
IL272306B (en) 2021-04-29
BR112016030968B1 (pt) 2023-11-21
EP3160470B1 (en) 2022-08-03
PL3160470T3 (pl) 2022-11-21
JP7035108B2 (ja) 2022-03-14

Similar Documents

Publication Publication Date Title
EA201790101A1 (ru) Аналоги придопидина, их получение и применение
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018500259A1 (en) Muscarinic agonists
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
IN2014CN00408A (ru)
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201890532A1 (ru) Новые аннелированные бензамиды
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CY1122170T1 (el) Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα
UA117154C2 (uk) Антагоністи s1p3
WO2016209978A3 (en) Thiol-ene based peptide stapling and uses thereof
MX2019007163A (es) Sales cristalinas y polimorfos de un antagonista de p2x3.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201792237A1 (ru) Фармацевтические составы
EA201591150A1 (ru) Твердая единая форма с высоким содержанием фексофенадина и способ ее получения
MX2017012022A (es) Compuestos organicos.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂